Enhancing CAR-T cell generation: optimizing non-viral engineering of resting T cells for improved cancer immunotherapy

Resting T cells are a highly desirable starting material for CAR-T cell production due to their persistence, capacity for self-renewal, and genomic stability. This article introduces a system that could be used to optimize the generation of CAR-T cells from resting T cells as part of a clinically relevant CAR-T cell therapy manufacturing workflow that helps ensure safety, efficacy, and scalability. The system, specifically designed for therapeutic cell engineering, harnesses a lower conductivity buffer to help improve transfection efficiency and cell viability with non-viral gene delivery.

Please enter your email to access content Read now